Joseph V. Simone, MD, of the Simone Consulting Company, reflects on the prospects for the future of safety and quality.
Kerin B. Adelson, MD, of the Yale Cancer Center, discusses an electronic decision support tool to capture staging data. This information allows automated reports for clinical trial screening, outcomes analysis, quality comparisons, and reporting. (Abstract 151)
Steven Shak, MD, of Genomic Health, discusses mortality among patients with early-stage hormone receptor–positive invasive breast cancer in the SEER database who were treated based on the 21-gene Recurrence Score results (Abstract 176).
Allison Kurian, MD, of Stanford University School of Medicine, discusses pressing questions about the clinical utility and value of extended genomic testing and other forms of precision medicine.
Lawrence N. Shulman, MD, of the University of Pennsylvania, discusses his paper, which explores lessons learned from analyses of the National Cancer Data Base. (Abstract 173)
Dawn L. Hershman, MD, of Columbia University Medical Center, summarizes a joint ASCO/NCI session on this important topic, including the challenges and solutions.
